Osivax Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 19

Osivax General Information

Description

Developer of universal vaccines designed to prevent globally impactful infectious diseases, starting with influenza. The company leverages its technology and acts as a universal vaccine against all existing and emerging coronavirus infections to prevent globally impactful contagious diseases, enabling medical practitioners to treat patients with cancer, influenza, malaria, and other infectious diseases effectively.

Contact Information

Website
www.osivax.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Swely Building C Slam
  • 70 Rue Saint Jean Dieu
  • 69007 Lyon
  • France
+33 04
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Swely Building C Slam
  • 70 Rue Saint Jean Dieu
  • 69007 Lyon
  • France
+33 04

Osivax Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Osivax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Secondary Transaction - Private 01-Mar-2026 Completed Clinical Trials - Phase 2
14. Grant 26-Aug-2025 Completed Clinical Trials - Phase 2
13. Later Stage VC (Series B1) 04-Mar-2025 Completed Clinical Trials - Phase 2
12. Grant 05-Dec-2023 Completed Clinical Trials - Phase 1
11. Later Stage VC 11-Jul-2023 Completed Clinical Trials - Phase 1
10. Grant 28-Mar-2023 Completed Clinical Trials - Phase 1
9. Accelerator/Incubator Completed Clinical Trials - Phase 1
8. Grant 23-Jun-2022 Completed Clinical Trials - Phase 1
7. Early Stage VC (Series B) 29-Jul-2021 $17.9M $35M Completed Clinical Trials - Phase 1
6. Grant 18-Mar-2020 $2.72M $17.1M Completed Clinical Trials - Phase 1
To view Osivax’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Osivax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of universal vaccines designed to prevent globally impactful infectious diseases, starting with influenza. The
Drug Discovery
Lyon, France
50 As of 2025

Abingdon, United Kingdom
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Osivax Competitors (21)

One of Osivax’s 21 competitors is Gylden Pharma, a Venture Capital-Backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gylden Pharma Venture Capital-Backed Abingdon, United Kingdom
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
RootPath Venture Capital-Backed Framingham, MA
Seekyo Venture Capital-Backed Poitiers, France
Step Pharma Venture Capital-Backed Saint-Genis-Pouilly, France
You’re viewing 5 of 21 competitors. Get the full list »

Osivax Patents

Osivax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023237601-A1 Mrna vaccine compositions and their use Pending 22-Mar-2022
AU-2023237601-A9 Mrna vaccine compositions and their use Pending 22-Mar-2022
EP-4496578-A1 Mrna vaccine compositions and their use Pending 22-Mar-2022
US-20240139300-A1 Mrna vaccine compositions and their use Pending 22-Mar-2022
WO-2023180394-A1 Mrna vaccine compositions and their use Inactive 22-Mar-2022 A61K31/7105
To view Osivax’s complete patent history, request access »

Osivax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Osivax Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
U.S. Department of Health and Human Services Government
Issarts Capital PE/Buyout Minority
Meiji Seika Pharma Corporation Minority
Le territoire en Wallonie Corporation Minority
Gates Foundation Not-For-Profit Venture Capital
You’re viewing 5 of 19 investors. Get the full list »

Osivax FAQs

  • When was Osivax founded?

    Osivax was founded in 2017.

  • Where is Osivax headquartered?

    Osivax is headquartered in Lyon, France.

  • What is the size of Osivax?

    Osivax has 50 total employees.

  • What industry is Osivax in?

    Osivax’s primary industry is Drug Discovery.

  • Is Osivax a private or public company?

    Osivax is a Private company.

  • What is Osivax’s current revenue?

    The current revenue for Osivax is .

  • How much funding has Osivax raised over time?

    Osivax has raised $45.4M.

  • Who are Osivax’s investors?

    U.S. Department of Health and Human Services, Issarts Capital, Meiji Seika Pharma, Le territoire en Wallonie, and Gates Foundation are 5 of 19 investors who have invested in Osivax.

  • Who are Osivax’s competitors?

    Gylden Pharma, Inovio Pharmaceuticals, RootPath, Seekyo, and Step Pharma are some of the 21 competitors of Osivax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process